Speaker Biography

Christoph Correll, is Professor of Psychiatry at The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New York, USA, as well as head of the department of child and adolescent psychiatry at the Charité University, Berlin, Germany. He completed his medical studies at the Free University of Berlin in Germany, and Dundee University Medical School in Scotland. He is board certified in general psychiatry and child and adolescent psychiatry, having completed both residencies at The Zucker Hillside Hospital in New York City.
Professor Correll’s research and clinical work focus on the identification, characterisation and treatment of adults and youth with severe psychiatric disorders, including the prodrome, first episode, multi-episode and refractory illness phase of psychotic and mood disorders. He further focuses on psychopharmacology, comparative effectiveness, and the risk–benefit evaluation of psychotropic medications.
Professor Correll has authored or co-authored over 500 journal articles. He has served on several expert consensus panels on the use of antipsychotics across a range of psychiatric disorders, is a reviewer for over 70 peer-reviewed journals and an editorial board member of 12 scientific journals. Professor Correll is the Principal Investigator or Steering Committee member of several large, federally funded grants. He has received over 40 national and international research awards and fellowships for his work. Since 2014, the year of inception of this metric, he has been listed every year by Thomson Reuters as one of “the most influential scientific minds” and “top 1% cited scientists in the area of psychiatry”.

Disclosure Statements

Sheppard Pratt holds the standard that its continuing medical education programs should be free of commercial bias and conflict of interest. In accord with Sheppard Pratt's Disclosure Policy, as well as standards of the Accreditation Council for Continuing Medical Education (ACCME) and the American Medical Association (AMA), all planners, reviewers and speakers have been asked to disclose any relationship he /she or their spouse/partner has with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 12 months. All planners, reviewers and speakers have also been asked to disclose any payments accepted for this lecture from any entity besides Sheppard Pratt Health System, and if there will be discussion of any products, services or off-label uses of product(s) during this presentation.

Christoph U. Correll, M.D. reports receiving payment for honoraria, consultancy or as an advisor for Alkermes, Allergan, Gerson, Lehrman Group, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, Medavante, Medscape, Neurocrine, Otsuka, Pfizer, ROVI, Sunovion, Takeda and Teva during the past 12 months. He will discuss medications and off-label uses of lamotrigine, valproate, oxcarbazepine, lamotrigine, lurasidone and ziprasidone for pediatric bipolar disorder in this presentation.

Event Planners/Reviewers Disclosures: The following event planners and/or reviewers are reported as having no financial interest, arrangement or affiliation with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, during the past 12 months: Ellen Mongan, M.D., Caroline Cahn, LCSW-C, Tom Flis, LCPC, Faith Dickerson, Ph.D., Robert Roca, M.D., Drew Pate, M.D., Meena Vimalananda, M.D., Briana Riemer, M.D. Ernestine Crosby, APRN, Darby Subotich, RN, MSN, Rick Wallace, RN, MSN, Jacqueline Williams-Porter, RN, MBA, Jennifer Tornabene, and Bonnie Katz.